INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF Time to stable dose paper rev 2_21_11.pdf (137KB) (no description provided) PDF
Title: Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients
Author(s): Cavallari, L.H.; Butler, C.; Langaee, T.Y.; Wardak, N.; Patel, S.R.; Viana, M.A.G.; Shapiro, N.L.; Nutescu, E.A.
Subject(s): warfarin genotype African American apolipoprotein E vitamin K
Abstract: Study Objective. To test the hypothesis that genotypes for proteins affecting vitamin K availability influence the duration of time required to achieve a stable warfarin dose in African-American patients. Design. Retrospective cohort study Setting. Pharmacist-managed antithrombosis clinic. Patients. Ninety-two African-American adults whose warfarin therapy was initiated between September 2, 1999, and July 8, 2009. Measurements and Main Results, During a routine anticoagulation clinic visit, a sample was collected from each patient for genetic analysis. Genotyping was performed for the following variants: apolipoprotein E epsilon 2, epsilon 3, and epsilon 4; NAD(P)H:quinone oxidoreductase (NQO1)*2; cytochrome P450 (CYP) 4F2 V433M; CYP2C9*2, *3, *5, *8, and *11; and vitamin K epoxide reductase complex 1 (VKORC1) -1639G>A. Patients' medical records were then reviewed, and data were collected retrospectively for each anticoagulation clinic visit during the first 6 months of warfarin therapy or until dose stabilization. The median time required to reach a stable warfarin dose, defined as the dose that produced therapeutic anticoagulation for three consecutive clinic visits, was 83 days. Compared with the 46 patients who achieved a stable warfarin dose within 83 days, the 46 patients who required longer durations for dose stabilization had a higher frequency of the apolipoprotein E epsilon 3/epsilon 3 genotype (37% vs 59%, p=0.037). Sixty-one percent of patients with the epsilon 3/epsilon 3 genotype versus 40% of those with an epsilon 2 or epsilon 4 allele had a delay in achieving a stable dose (p=0.037). Neither the CYP4F2 nor NQO1 genotype was associated with warfarin dose stabilization. Conclusion. Our data support the hypothesis that the apolipoprotein E genotype is associated with duration of time to reach a stable warfarin dose in African-American patients. Further insight into the genetic effects on warfarin dose stabilization could reveal novel methods to improve anticoagulation control during the warfarin initiation period.
Issue Date: 2011-08
Publisher: IOS Press
Citation Info: Cavallari, L. H., Butler, C., Langaee, T. Y., Wardak, N., Patel, S. R., Viana, M. A. G., Shapiro, N. L., & Nutescu, E. A. 2011. Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients. Pharmacotherapy, 31(8): 785-792. DOI: 10.1592/phco.31.8.785
Type: Article
Description: © 2011 by IOS Press, Pharmacotherapy Post print version of article may differ from published version. The definitive version is available through IOS Press at DOI:10.1592/phco.31.8.785
ISSN: 0277-0008
Sponsor: This study was supported by an American Foundation for Pharmaceutical Education New Investigator Award and a University of Illinois Hans Vahlteich Pharmacy Endowment Award to L.H.C.
Date Available in INDIGO: 2012-08-21

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 393
China 154
Russian Federation 34
Germany 29
United Kingdom 15


My Account


Access Key